Bharat Biotech, IVI launch Chikungunya Vaccine Phase 2/3 trial in Costa Rica

CEPI first partnered with IVI and Bharat Biotech in June 2020, providing up to USD 14.1 million for vaccine manufacturing and clinical development of the BBV87 vaccine candidate.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news

Related Links:

Condition:   Chikungunya Virus Interventions:   Biological: CHIKV VLP/adjuvant;   Biological: Placebo Sponsor:   Emergent BioSolutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Faster vaccine development could be a step closer thanks to £ 4 million investment to Imophoron Ltd, a Bristol University biotech start-up developing a novel, next generation rapid-response vaccine platform called ADDomer ™ . Imophoron will use the investment to bring ADDomer vaccines to clinical stage, initially targeting three viruses, RSV (respiratory syncytial virus), COVID-19, and mosquito-borne Chikungunya.
Source: University of Bristol news - Category: Universities & Medical Training Tags: Announcements, Business and Enterprise, Grants and Awards, Health, International, Research; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School, Faculty of Life Sciences, Faculty of Life Sciences, School of Biochemistry, Faculty Source Type: news
Chikungunya virus (CHIKV) is currently one of the most relevant arboviruses to public health. It is a member of the Togaviridae family and alphavirus genus and causes an arthritogenic disease known as chikungunya fever (CHIKF). It is characterized by a multifaceted disease, which is distinguished from other arbovirus infections by the intense and debilitating arthralgia that can last for months or years in some individuals. Despite the great social and economic burden caused by CHIKV infection, there is no vaccine or specific antiviral drugs currently available. Recent outbreaks have shown a change in the severity profile ...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Condition:   Chikungunya Virus Intervention:   Biological: CHIKV VLP, adjuvanted Sponsor:   Emergent BioSolutions Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Am J Trop Med Hyg. 2021 Sep 27:tpmd210454. doi: 10.4269/ajtmh.21-0454. Online ahead of print.ABSTRACTAedes albopictus is a highly invasive mosquito species and a vector of human arboviral diseases including dengue, chikungunya, and Zika. There are no effective drugs or vaccines for the treatment or prevention of most of these diseases, so the primary option for disease prevention and control is to target mosquitoes, often using insecticides. Despite vector control efforts, cases of arboviral diseases are increasing in Bangladesh and it is important to understand if this escalation is associated with the presence of insecti...
Source: The American Journal of Tropical Medicine and Hygiene - Category: Tropical Medicine Authors: Source Type: research
More News: Biotechnology | Chikungunya | Costa Rica Health | Pharmaceuticals | Vaccines